NeurAxis, Inc. (NRXS)
:NRXS
Want to see NRXS full AI Analyst Report?
Earnings Data
Report Date
Sep 17, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.22Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented clear early commercial progress: strong sequential and year-over-year growth, higher ASP and gross margins, improving KPIs, and early VA traction. However, substantial challenges remain—incomplete and uneven payer coverage, modest prior authorization approvals, continued operating losses, an upcoming sizable non-cash stock charge, and a large revenue gap to reach cash-flow breakeven. Management’s tone was optimistic and execution-focused, but the company remains dependent on accelerating payer policy adoption and deepening usage within priority accounts.Company Guidance
Strong Revenue Growth
Q1 FY2026 revenue was $1.6M versus $896K in Q1 FY2025, an 80% year-over-year increase and the strongest quarterly revenue in company history.
Improved Average Selling Price and Unit Mix
IB-Stim average selling price rose to $1,017 in Q1 FY2026 from $766 in Q1 FY2025, a 33% increase driven by a shift from discounted financial assistance toward full reimbursement payers; unit deliveries increased 32% year-over-year.
Gross Margin Expansion
Gross margin expanded to 86.4% in Q1 FY2026 from 84.4% in Q1 FY2025, a 200-basis-point improvement attributed to better payer mix and Category 1 CPT code adoption.
Meaningful KPI Improvements
Internal prior authorization approval rate for supported children's hospitals rose to 32% in Q1 FY2026 from 12% in 2025; number of ordering accounts increased to 66 from 56 (+18%); revenue per ordering account rose to $24K from $16K (+53%).
Payer Coverage Progress & CPT Code Impact
Category 1 CPT code for PENFS went into effect Jan 1, 2026, supporting reimbursement infrastructure; company reports >100M covered lives (101M) and improved access to medical directors at several large payers.
VA Channel Early Traction
Awarded federal supply schedule enabling VA access; multiple VA facilities already placing orders and many more activating despite typical long VA timelines; VA represents a complementary large channel (VA serves ~7M patients; functional dyspepsia ~3%).
Stronger Liquidity and Reduced Burn
Cash on hand was $7.1M at March 31, 2026 and management raised an incremental $2.1M afterward (approx. $8M total); Q1 free cash outflow improved to $1.2M vs $1.6M prior year and quarterly burn is expected to trend toward ~$1M or less for the rest of the year.
NRXS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NRXS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $8.15 | $8.27 | +1.47% |
Mar 19, 2026 | $6.99 | $7.16 | +2.43% |
Nov 11, 2025 | $2.56 | $2.41 | -5.86% |
Aug 12, 2025 | $2.43 | $2.49 | +2.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does NeurAxis, Inc. (NRXS) report earnings?
NeurAxis, Inc. (NRXS) is schdueled to report earning on Sep 17, 2026, Before Open (Confirmed).
What is NeurAxis, Inc. (NRXS) earnings time?
NeurAxis, Inc. (NRXS) earnings time is at Sep 17, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NRXS EPS forecast?
NRXS EPS forecast for the fiscal quarter 2026 (Q2) is -0.17.